September 4, 2022
In August, ASBM recorded two new entries in its ongoing continuing education (CE) series in partnership with the Ohio State University College of Pharmacy. These represent part 4 and 6 of the 7-part series covering a wide range of biosimilar policy issues. View the previous three entries here. Module 4: Physician Perspectives on Biosimilars In this module, […]
September 3, 2022
On August 31st, several ASBM representatives joined Tiffany Westrich-Robertson, CEO of the International Foundation for Autoimmune & Autoinflammatory Diseases, to record an episode of the AI Arthritis Voices 360 podcast. The episode discussed examined policy issues surrounding biosimilars and how these affect patients. ASBM was represented in the discussion by Executive Director Michael Reilly; Chairman Ralph McKibbin, […]
June 24, 2022
On June 20th, ASBM Chairman Ralph McKibbin, MD, FACP, FACG, AGAF presented a poster at the DIA Global Annual Meeting 2022 in Chicago, IL. The poster was entitled “U.S. Physician Perspectives on Biosimilar Substitution and Reimbursement Practices” and featured results from ASBM’s 2021 survey of 401 U.S. physicians. Among its key findings: Nearly all physicians surveyed expressed […]
June 1, 2022
On May 31st, the Ohio State University College of Pharmacy released a series of promotional videos for its 7-hour continuing education (CE) program on biosimilars. The videos consist of an overview of the educational program featuring all the presenters, as well as a biographical sketch of each presenter. The program was developed in partnership with ASBM […]
June 1, 2022
On June 29th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled “Key Factors for Successful Uptake of Biosimilars: Europe and the US: measures taken for improving biosimilar uptake and the potential role of healthcare providers and patients”. The event featured a keynote presentation by former U.S. Deputy Secretary of Health and Human Services […]
June 1, 2022
On June 29th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled “Key Factors for Successful Uptake of Biosimilars: Europe and the US: measures taken for improving biosimilar uptake and the potential role of healthcare providers and patients”. The event featured a keynote presentation by former U.S. Deputy Secretary of Health and Human Services […]
May 24, 2022
On April 13th, the U.S. Food and Drug Administration (FDA) and The University of Maryland Center of Excellence in Regulatory Science (M-CERSI) held an educational webinar entitled “Biosimilars: A Decade of Experience and Future Directions-Strategies for Improving Biosimilar Adoption and the Potential Role of Clinical Pharmacology”. In the workshop, leading academic clinicians with specialties in oncology, […]
May 5, 2022
On June 20th, ASBM Chairman Ralph McKibbin, MD will present a poster entitled “Physician Perspectives on Biosimilar Substitution and Reimbursement Practices” at the 2022 DIA Global Annual Meeting in Chicago, IL. The poster is based on the findings of ASBM’s September 2021 survey of 401 U.S. physicians. While topline findings have been shared privately in meetings […]
May 5, 2022
On June 20th, ASBM Chairman Ralph McKibbin, MD will present a poster entitled “Physician Perspectives on Biosimilar Substitution and Reimbursement Practices” at the 2022 DIA Global Annual Meeting in Chicago, IL. The poster is based on the findings of ASBM’s September 2021 survey of 401 U.S. physicians. While topline findings have been shared privately in meetings […]
April 29, 2022
On April 29th, ASBM submitted comments to Health Canada as part of a stakeholder consultation on its draft Handbook for healthcare professionals on biosimilar biologic drugs. One key area of focus for ASBM’s comments was mixed messaging surrounding biosimilar equivalence and switching, including language which implies, inaccurately, that Canada’s policies were consistent with those of regulators in […]
